Основная статистика
| LEI | 549300CATCWKUQ6G5854 |
| CIK | 890821 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Enveric Biosciences, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| September 2, 2025 |
Exhibit 99.1 Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA Move aligns with company’s vision to leverage the Greater Boston biotech hub’s scientific and financial ecosystem and advance EB-003 into first-in-human trial in 2026 CAMBRIDGE, Mass., September 2, 2025 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generati |
|
| September 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 2, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| August 29, 2025 |
Exhibit 99.1 |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 August 29, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction (Commission (I.R.S. Employer |
|
| August 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934 August 26, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| August 14, 2025 |
Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results Exhibit 99.1 Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results Q2 marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling progress, and continued strengthening of Enveric’s differentiated neuroplastogen pipeline and IP platform. Q2 financial results were consistent with overall performance o |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| August 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 14, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| June 3, 2025 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 29, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 14, 2025 |
Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results Exhibit 99.1 Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results Corporate, Business and Product Development Highlights: ● Unveiled EVM401 Series with new U.S. Patent for mescaline derivative compounds ● Added to suite of intellectual property for EB-003, a neuroplastogen targeting undertreated mental health indications ● Signed two licensing agreements for cannabinoid-C |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| May 14, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 14, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| April 16, 2025 |
April 16, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| April 14, 2025 |
Letter from Marcum LLP, dated April 14, 2025 addressed to the Securities and Exchange Commission. Exhibit 16.1 April 14, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Re: Enveric Biosciences, Inc. Commission File Number 001-38286 Commissioners: We have read the statements made by Enveric Biosciences, Inc. under Item 4.01 of its Form 8-K dated April 14, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or |
|
| April 14, 2025 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 14, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| April 10, 2025 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| April 10, 2025 |
Exhibit 1.2 AT THE MARKET OFFERING AGREEMENT April 9, 2025 H.C. Wainwright & Co., LLC 430 Park Avenue New York, New York 10022 Ladies and Gentlemen: Enveric Biosciences, Inc., a corporation organized under the laws of Delaware (the “Company”), confirms its agreement (this “Agreement”) with H.C. Wainwright & Co., LLC (the “Manager”) as follows: 1. Definitions. The terms that follow, when used in th |
|
| April 10, 2025 |
As filed with the U.S. Securities and Exchange Commission on April 9, 2025 As filed with the U.S. Securities and Exchange Commission on April 9, 2025 Registration No. 333-280721 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENVERIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4484725 (State or other jurisdiction of incorpor |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| March 31, 2025 |
Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024 Product Development Highlights: ● Advanced pre-IND and research activities including confirmation of oral bioavailability and significant brain exposure for EB-003, a novel potential first-in-class neuroplastogenic molecule designed to treat severe mental health di |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 31, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 28, 2025 |
Exhibit 10.37 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL EXCLUSIVE LICENSE AGREEMENT This EXCLUSIVE LICENSE AGREEMENT (the “Agreement”) is made and entered as of November 7, 2024 (the “Effective Date”), by and between Enveric Biosciences, Inc., a De |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, IN |
|
| March 28, 2025 |
Exhibit 10.14 RESTRICTED STOCK AWARD AGREEMENT ENVERIC BIOSCIENCES, INC. 2020 LONG-TERM INCENTIVE PLAN 1. Grant of Award. Pursuant to the Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Plan”) for Employees, Contractors, and Outside Directors of Enveric Biosciences, Inc., a Delaware corporation (the “Company”), the Company grants to (the “Participant”) an Award of Restricted Stock in |
|
| March 28, 2025 |
SUBSIDIARIES OF ENVERIC BIOSCIENCES, INC. Exhibit 21 SUBSIDIARIES OF ENVERIC BIOSCIENCES, INC. Subsidiary Jurisdiction of Organization Jay Pharma Inc. Ontario, Canada 1306432 B.C. Unlimited Liability Company British Columbia, Canada 1236567 B.C. Unlimited Liability Company British Columbia, Canada Enveric Biosciences Canada, Inc. British Columbia, Canada MagicMed USA, Inc. Massachusetts, USA Akos Biosciences, Inc. Delaware, USA Enveric Th |
|
| March 24, 2025 |
Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan Exhibit 10.1 ENVERIC BIOSCIENCES, INC. 2020 LONG-TERM INCENTIVE PLAN, AS AMENDED The Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Original Plan”), was adopted by the Board of Directors of Enveric Biosciences, Inc., a Delaware corporation (the “Company”), effective as of December 31, 2020 (the “Effective Date”), was amended as of July 14, 2022 and was further amended as of November |
|
| March 24, 2025 |
As filed with the Securities and Exchange Commission on March 24, 2025 As filed with the Securities and Exchange Commission on March 24, 2025 Registration No. |
|
| March 24, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Enveric Biosciences, Inc. |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 4, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| February 26, 2025 |
Investor Presentation Q1 2025 (furnished pursuant to Item 7.01) Exhibit 99.1 |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 26, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| February 5, 2025 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. |
|
| February 3, 2025 |
Enveric Biosciences Announces Closing of $5 Million Public Offering Exhibit 99.2 Enveric Biosciences Announces Closing of $5 Million Public Offering CAMBRIDGE, Mass., February 3, 2025 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the closing of its pr |
|
| February 3, 2025 |
Filed Pursuant to Rule 424(b)(4) Registration No. 333-284277 PROSPECTUS Enveric Biosciences, Inc. 1,229,330 Shares of Common Stock 1,666,666 Series A Warrants to Purchase up to 1,666,666 Shares of Common Stock 1,666,666 Series B Warrants to Purchase up to 1,666,666 Shares of Common Stock 437,336 Pre-Funded Warrants to Purchase 437,336 Shares of Common Stock 3,770,668 Shares of Common Stock Underly |
|
| February 3, 2025 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 30, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| February 3, 2025 |
Enveric Biosciences Announces Pricing of $5 Million Public Offering Exhibit 99.1 Enveric Biosciences Announces Pricing of $5 Million Public Offering CAMBRIDGE, Mass., January 30, 2025 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced the pricing of a publ |
|
| January 30, 2025 |
Amendment to the Wainwright Engagement Letter, dated January 14, 2025 Exhibit 1.2 Execution Version January 14, 2025 STRICTLY CONFIDENTIAL Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, Florida 34103 Attn: Joseph Tucker, Ph.D., Chief Executive Officer Dear Mr. Tucker: Reference is made to the engagement letter (the “Engagement Letter”), dated December 8, 2024, by and between Enveric Biosciences, Inc. (the “Company”) and H.C. Wainwright & Co., LLC |
|
| January 30, 2025 |
Form of Securities Purchase Agreement Exhibit 10.33 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of , 2025, between Enveric Biosciences, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set |
|
| January 30, 2025 |
As filed with the Securities and Exchange Commission on January 30, 2025 As filed with the Securities and Exchange Commission on January 30, 2025 Registration No. |
|
| January 30, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Enveric Biosciences, Inc. |
|
| January 30, 2025 |
Exhibit 1.1 Execution Version December 8, 2024 STRICTLY CONFIDENTIAL Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, Florida 34103 Attn: Joseph Tucker, Ph.D., Chief Executive Officer Dear Dr. Tucker: This letter agreement (this “Agreement”) constitutes the agreement between Enveric Biosciences, Inc. (the “Company”) and H.C. Wainwright & Co., LLC (“Wainwright”), that Wainwright sh |
|
| January 30, 2025 |
Exhibit 4.15 SERIES A COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Warrant Shares: Issue Date: , 2025 THIS SERIES A COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Stockholder Approva |
|
| January 30, 2025 |
January 30, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 30, 2025 |
Exhibit 4.16 SERIES B COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Warrant Shares: Issue Date: , 2025 THIS SERIES B COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the [Stockholder Approva |
|
| January 30, 2025 |
As filed with the Securities and Exchange Commission on January 30, 2025 As filed with the Securities and Exchange Commission on January 30, 2025 Registration Statement No. |
|
| January 30, 2025 |
Exhibit 4.14 EXHIBIT A-2 PRE-FUNDED COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Warrant Shares: Issue Date: , 2025 Initial Exercise Date: , 2025 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at |
|
| January 30, 2025 |
Exhibit 4.17 EXHIBIT A-1 PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT Enveric Biosciences, Inc. Warrant Shares: Issue Date: , 2025 THIS PLACEMENT AGENT COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or afte |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 24, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of inco |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 17, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| January 21, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ENVERIC BIOSCIENCES, INC. Enveric Biosciences, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware, does hereby certify that: 1. The name of the Corporation is Enveric Biosciences, Inc. 2. The Board of Directors of the C |
|
| January 14, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Enveric Biosciences, Inc. |
|
| January 14, 2025 |
As filed with the Securities and Exchange Commission on January 14, 2025 As filed with the Securities and Exchange Commission on January 14, 2025 Registration No. |
|
| January 3, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 3, 2025 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| January 3, 2025 |
Investor Presentation Q1 2025 (furnished pursuant to Item 7.01) Exhibit 99.1 |
|
| December 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| December 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| November 22, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 20, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2024 |
ENVB / Enveric Biosciences, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| November 14, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 14, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| November 14, 2024 |
Exhibit 99.1 Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results Advanced pre-IND activities and research for lead candidate, EB-003, a novel neuroplastogenic molecule designed to treat severe mental health disorders Announced the expansion of patent protection for a broad range of molecules in its EVM301 portfolio, including five previously unannounced US patents Out-li |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIEN |
|
| November 14, 2024 |
Exhibit 10.1 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. EXCLUSIVE LICENSE AGREEMENT Pharmaceutical and OTC Cannabinoid Compounds for Treatment of Radiation Dermatitis THIS EXCLUSIVE LICENSE AGREEMENT (the “Agreement”), is made and entered on this 1 |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Enveric Biosciences, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 29405E208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| November 12, 2024 |
ENVB / Enveric Biosciences, Inc. / AdvisorShares Trust Passive Investment SC 13G/A 1 sch13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Enveric Biosciences, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 29405E208 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of the Statement) Check the appropriate box to |
|
| November 12, 2024 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 7, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| November 12, 2024 |
Exhibit 99.1 Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002 Agreement includes development and sales milestones payments potentially totaling up to $62 million as well as tiered single digit royalties on future sales CAMBRIDGE, Mass., November 12, 2024 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedica |
|
| September 12, 2024 |
4,900,000 Shares of Common Stock Enveric Biosciences, Inc. Filed Pursuant to Rule 424(b)(4) Registration No. 333-281934 PROSPECTUS 4,900,000 Shares of Common Stock Enveric Biosciences, Inc. This prospectus relates to the offer and resale of up to 4,900,000 shares of our common stock, par value $0.01 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock bein |
|
| September 10, 2024 |
September 10, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| September 4, 2024 |
As filed with the Securities and Exchange Commission on September 4, 2024 As filed with the Securities and Exchange Commission on September 4, 2024 Registration No. |
|
| September 4, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Enveric Biosciences, Inc. |
|
| August 22, 2024 |
Investor Presentation Q3 2024 (furnished pursuant to Item 7.01) Exhibit 99.1 |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 22, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| August 12, 2024 |
Exhibit 99.1 Enveric Biosciences Reports Second Quarter 2024 Financial and Corporate Results Prioritized EB-003 as lead development candidate. EB-003 is a novel, non-hallucinogenic neuroplastogenic molecule designed to treat severe mental health disorders Announced preclinical results confirming oral bioavailability and significant brain exposure of EB-003, supporting expedited development strateg |
|
| August 12, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 12, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| July 15, 2024 |
Exhibit 99.1 Aries Science & Technology and Enveric Biosciences Announce Licensing Agreement Aries to clinically develop and market Enveric’s patented product for radiation dermatitis CAMBRIDGE, Mass., July 15, 2024 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric”), a biotechnology company dedicated to the development of novel neuroplastogens for the treatment of neuropsychiatric disorders, and Ari |
|
| July 15, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 10, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| July 8, 2024 |
Exhibit 107 CALCULATION OF REGISTRATION FEE Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Common Stock, $0. |
|
| July 8, 2024 |
As filed with the U.S. Securities and Exchange Commission on July 8, 2024 As filed with the U.S. Securities and Exchange Commission on July 8, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ENVERIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 95-4484725 (State or other jurisdiction of incorporation or organization) (I. |
|
| May 29, 2024 |
Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 28, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 21, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 17, 2024 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 16, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 15, 2024 |
Exhibit 99.1 Enveric Biosciences Reports First Quarter 2024 Financial and Corporate Results Revealed seven classes of promising novel drug candidates discovered using Enveric’s Psybrary™ and PsyAI™ drug discovery and artificial intelligence (AI) platforms Launched business development campaign that resulted in the execution of seven non-binding term sheets with four strategic partners that upon en |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2024 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| May 15, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 15, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 3, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-257690 PROSPECTUS SUPPLEMENT (To Prospectus dated July 9, 2021) 458,000 Shares of Common Stock We are offering 458,000 shares of our common stock, par value $0.01 per share, at a deemed offering price of $0.94 per share directly to certain investors in a registered direct offering pursuant to this prospectus supplement, the accompanying prospec |
|
| May 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 3, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission Fi |
|
| May 3, 2024 |
Exhibit 10.1 ENVERIC BIOSCIENCES, INC. COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is entered into as of May 3, 2024 (“Execution Date”), by and between Enveric Biosciences, Inc., a Delaware corporation (the “Company”), and the investor set forth on the signature page hereto (the “Investor”). WHEREAS, on December 28, 2023, the Company entered into warrant |
|
| April 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 27, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 26, 2024 |
Exhibit 99.1 Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023 Product Development Highlights: ● Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. ● Started IND-enab |
|
| March 26, 2024 |
Exhibit 14 ENVERIC BIOSCIENCES, INC. CORPORATE CODE OF CONDUCT AND ETHICS AND WHISTLEBLOWER POLICY Effective December 31, 2020 INTRODUCTION Enveric Biosciences, Inc. (“we” or the “Company”) has adopted this Corporate Code of Conduct and Ethics and Whistleblower Policy (the “Code”) to provide our associates, as defined below, with a clear understanding of the principles of business conduct and ethi |
|
| March 26, 2024 |
Exhibit 97 ENVERIC BIOSCIENCES, INC. CLAWBACK POLICY Introduction The Board of Directors (the “Board”) of Enveric Biosciences, Inc. (the “Company”) believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability. The Board has therefore adopted this Clawback Policy (the “Policy”), which provides for the rec |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, IN |
|
| March 26, 2024 |
Exhibit 19 Enveric Biosciences Inc. INSIDER TRADING POLICY This Insider Trading Policy (the “Policy”) provides guidelines to all employees and officers of Enveric Biosciences, Inc. and its affiliates (the “Company”) as well as members of the Company’s Board of Directors (the “Directors”) with respect to transactions in the Company’s securities, and codifies the Company’s standards on trading and e |
|
| March 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 26, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 19, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 19, 2024 |
Exhibit 99.1 Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease Second biotechnology company to potentially out-license novel compounds from Enveric’s portfolio of assets with possible significant milestone payments and royalties CAMBRIDGE, Mass., March 19, 2024 – E |
|
| March 11, 2024 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-257690 PROSPECTUS SUPPLEMENT (To Prospectus dated July 9, 2021) 228,690 Shares of Common Stock We are offering 228,690 shares of our common stock, par value $0.01 per share, at a deemed offering price of $1.41 per share directly to certain investors in a registered direct offering pursuant to this prospectus supplement, the accompanying prospec |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 8, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 11, 2024 |
Exhibit 10.1 ENVERIC BIOSCIENCES. INC. COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT (the “Agreement”) is entered into as of March 8, 2024, by and between Enveric Biosciences, Inc., a Delaware corporation (the “Company”), and the investor set forth on the signature page hereto (the “Investor”). WHEREAS, on December 28, 2023, the Company entered into warrant exercise induceme |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 29, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| February 29, 2024 |
Exhibit 99.1 Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds Potentially significant milestone payments and execution fees if all development and sales criteria are met for all three agreements. CAMBRIDGE, Mass., February 29, 2024 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicate |
|
| February 21, 2024 |
Exhibit 99.1 Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders Novel compounds protected under Enveric’s intellectual property portfolio provide potential licensing opportunities and non-dilutive revenue streams. CAMBRIDGE, Mass., February 21, 2024 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company” |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 21, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2024 |
US29405E2081 / ENVERIC BIOSCIENCES INC / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 6, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| February 6, 2024 |
SC 13G/A 1 ea192881-13ga2intraenveric.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enveric Biosciences, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 29405E208 (CUSIP Number) December 31, 2023 (Date of Event Which Re |
|
| February 5, 2024 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enveric Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29405E208 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu |
|
| January 24, 2024 |
Enveric Biosciences Inc. 2,244,000 Shares of Common Stock PROSPECTUS Filed Pursuant to Rule 424(b)(3) Registration No. 333-276473 Enveric Biosciences Inc. 2,244,000 Shares of Common Stock This prospectus relates to the resale of up to 2,244,000 shares of Enveric Biosciences, Inc. (the “Company,” “we,” or “us”) common stock, par value $0.01 per share, by the selling stockholders named in this prospectus or its permitted transferees. The shares of common s |
|
| January 19, 2024 |
January 19, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 11, 2024 |
As Filed with the Securities and Exchange Commission on January 11, 2024 As Filed with the Securities and Exchange Commission on January 11, 2024 Registration No. |
|
| January 11, 2024 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 ENVERIC BIOSCIENCES, INC. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, par value $0.01 per share Other 2,244,000 |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 8, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 January 3, 2024 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| January 3, 2024 |
Exhibit 99.1 Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission CAMBRIDGE, Mass., January 3, 2024 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic |
|
| December 29, 2023 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTR |
|
| December 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 28, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| December 29, 2023 |
Exhibit 99.1 Enveric Biosciences Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $1.8 Million Gross Proceeds Priced At-the-Market CAMBRIDGE, Mass., December 29, 2023 (BUSINESS WIRE) – Enveric Biosciences (NASDAQ: ENVB (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for th |
|
| December 29, 2023 |
Exhibit 10.1 December 28, 2023 [Name and address of warrant holder] Re: Reprice and Reload Offer of Common Stock Purchase Warrants To Whom It May Concern: Enveric Biosciences, Inc. (the “Company”) is pleased to offer to you the opportunity to receive new Common Stock purchase warrants of the Company in consideration for the exercise of (i) the Common Stock purchase warrants issued to you on or abo |
|
| December 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 28, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| December 28, 2023 |
Exhibit 99.1 Enveric Biosciences Selects EB-003 as Lead Drug Candidate from EVM301 Series Enveric to initiate preclinical development of EB-003 in 2024 in preparation for IND submission CAMBRIDGE, Mass., December 28, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for |
|
| December 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 27, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| December 27, 2023 |
Exhibit 99.1 Enveric Biosciences Reports Year End Progress for Preclinical Development of Lead Prodrug Candidate EB-373 The ongoing GLP Safety and Toxicology Program of EB-373 is thus far proceeding on time with favorable results CAMBRIDGE, Mass., December 27, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuro |
|
| December 6, 2023 |
1,279,880 Shares of Common Stock Enveric Biosciences, Inc. PROSPECTUS Filed Pursuant to Rule 424(b)(4) Registration No. 333-275380 1,279,880 Shares of Common Stock Enveric Biosciences, Inc. This prospectus relates to the offer and resale of up to 1,279,880 shares of our common stock, par value $0.01 per share, by Lincoln Park Capital Fund, LLC, which we refer to in this prospectus as Lincoln Park or the selling stockholder. The shares of common stock bein |
|
| December 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 December 5, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| December 5, 2023 |
Exhibit 99.1 Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived Compounds Three novel neuroplastic compounds identified with plans to advance one into expedited preclinical development in 2024 CAMBRIDGE, Mass., December 5, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Comp |
|
| December 4, 2023 |
December 4, 2023 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| December 1, 2023 |
As filed with the Securities and Exchange Commission on December 1, 2023 As filed with the Securities and Exchange Commission on December 1, 2023 Registration No. |
|
| November 29, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 29, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| November 29, 2023 |
Exhibit 99.1 Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin Derivatives Expands intellectual property portfolio with composition of matter and methods of use claims governing Enveric’s EVM301 Series of drug candidates CAMBRIDGE, Mass., November 29, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company |
|
| November 22, 2023 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 21, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIEN |
|
| November 13, 2023 |
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results Exhibit 99.1 Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results EVM-301 Series ● Presented and published leading scientific research describing development and screening methods for non-hallucinogenic, neuroplastogenic drug candidates in Enveric’s EVM301 Series of candidates targeting the treatment of mental health disorders ● Announced AI-powered drug candidate generat |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 ENVERIC BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commis |
|
| November 8, 2023 |
Exhibit 10.43 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of November 3, 2023, is made by and between ENVERIC BIOSCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Inve |
|
| November 8, 2023 |
As filed with the Securities and Exchange Commission on November 7, 2023 As filed with the Securities and Exchange Commission on November 7, 2023 Registration No. |
|
| November 8, 2023 |
Exhibit 10.44 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 3, 2023, is entered into by and between ENVERIC BIOSCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherw |
|
| November 8, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Enveric Biosciences, Inc. |
|
| November 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 3, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| November 6, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of November 3, 2023, is entered into by and between ENVERIC BIOSCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (together with its permitted assigns, the “Investor”). Capitalized terms used herein and not otherwi |
|
| November 6, 2023 |
Exhibit 10.1 PURCHASE AGREEMENT THIS PURCHASE AGREEMENT (the “Agreement”), dated as of November 3, 2023, is made by and between ENVERIC BIOSCIENCES, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”). WHEREAS: Subject to the terms and conditions set forth in this Agreement, the Company wishes to sell to the Inves |
|
| November 2, 2023 |
Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan, as amended Exhibit 10.1 ENVERIC BIOSCIENCES, INC. 2020 LONG-TERM INCENTIVE PLAN, AS AMENDED The Enveric Biosciences, Inc. 2020 Long-Term Incentive Plan (the “Original Plan”), was adopted by the Board of Directors of Enveric Biosciences, Inc., a Delaware corporation (the “Company”), effective as of December 31, 2020 (the “Effective Date”), was amended as of July 14, 2022 and was further amended as of November |
|
| November 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 November 2, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| October 31, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 31, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| October 31, 2023 |
Exhibit 99.1 Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of Psilocin Expands its intellectual property portfolio with composition of matter claims governing lead clinical candidate, EB-373, a psilocin prodrug being developed for the treatment of depression and anxiety disorders. CAMBRIDGE, Mas |
|
| October 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 20, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| October 20, 2023 |
Exhibit 99.1 Enveric Biosciences to Present at the Centurion One 5th Global Summit CEO Joseph Tucker, Ph.D., to deliver company presentation and participate in panel discussion CAMBRIDGE, Mass., October 20, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatm |
|
| October 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 18, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| October 18, 2023 |
Exhibit 99.1 Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric Disorders Key preclinical milestone designed to establish safety profile and maximum tolerated dose for anticipated clinical trial of EB-373 CAMBRIDGE, Mass., October 18, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or t |
|
| October 11, 2023 |
Exhibit 99.1 Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development Summit Presentations highlight research involving Enveric’s EVM301 Series of non-hallucinogenic neuroplastogens and the company’s lead product candidate, EB-373 CAMBRIDGE, Mass., October 11, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company |
|
| October 11, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 11, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| October 3, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 3, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| October 3, 2023 |
Exhibit 99.1 Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic Candidates The Psybrary™ portfolio includes numerous unique, previously unreported molecules, which are protected by Enveric’s expansive and growing intellectual property estate CAMBRIDGE, Mass., October 3, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), |
|
| September 27, 2023 |
Exhibit 99.1 Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological Chemistry Paper co-authored by Enveric researchers describes the discovery of a key cane toad enzyme and its application to the biosynthesis of novel indolethylamine-type drug candidates with potential use in psychiatric me |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 27, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commis |
|
| September 20, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 20, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commis |
|
| September 20, 2023 |
Exhibit 99.1 Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug Candidates Claims to novel composition of matter and pharmaceutical drug formulations encompass EVM301 Series of drug candidates, targeting various difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallu |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| September 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 18, 2023 |
Exhibit 99.1 Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023 Poster details advances in screening for non-hallucinogenic, neuroplastogen drug candidates for the treatment of mental health disorders CAMBRIDGE, Mass., September 18, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biot |
|
| September 18, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 18, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commis |
|
| September 11, 2023 |
Exhibit 99.1 Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine Derivatives Enveric utilizing AI-backed 3D modeling to identify potential non-hallucinogenic, neuroplastic tryptamine derivative NCEs for its EVM301 Series CAMBRIDGE, Mass., September 11, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the |
|
| September 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 11, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commis |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 5, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| September 5, 2023 |
Exhibit 99.1 Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine Derivatives New patent provides additional composition of matter and methods of use claims for Enveric’s tryptamine-derived prodrugs including EB-373, a new chemical entity psilocin prodrug CAMBRIDGE, Mass., September 5, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a |
|
| September 1, 2023 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-257690 PROSPECTUS SUPPLEMENT (To Prospectus dated July 9, 2021) Up to $2,392,514 Common Stock We have entered into an Equity Distribution Agreement, or the Distribution Agreement, with Canaccord Genuity LLC, or Canaccord, acting as sales agent, on September 1, 2023, relating to our shares of common stock, par value $0.01 per share (the “Common |
|
| September 1, 2023 |
Exhibit 1.1 Enveric Biosciences, Inc. Common Stock (par value $0.01 per share) $10,000,000 EQUITY DISTRIBUTION AGREEMENT September 1, 2023 Canaccord Genuity LLC 99 High Street, 12th Floor Boston, Massachusetts 02110 Ladies and Gentlemen: Enveric Biosciences, Inc., a Delaware corporation (the “Company”), confirms this agreement (this “Agreement”) with Canaccord Genuity LLC (the “Manager”) as follow |
|
| September 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 1, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| August 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 28, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| August 28, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 28, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| August 28, 2023 |
Exhibit 99.1 Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived Prodrugs Composition of matter and methods of use claims encompass EB-373, Enveric’s new chemical entity psilocin prodrug being developed for the treatment of anxiety disorder CAMBRIDGE, Mass., August 28, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a |
|
| August 28, 2023 |
Exhibit 99.1 |
|
| August 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 21, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| August 21, 2023 |
Exhibit 99.1 Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical Program High purity of manufactured prodrug product allows Enveric and partners to ship EB-373 without being subject to restrictions required for controlled substances CAMBRIDGE, Mass., August 21, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechn |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2023 ENVERIC BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| August 14, 2023 |
Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results Exhibit 99.1 Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial Results ● Advanced preclinical pipeline of neuroplastogenic small-molecule therapeutics targeting neuronal atrophy to offer a first-in-class treatment of mental health disorders ● Secured multiple Notices of Allowance and select issuances from the United States Patent and Trademark Office (the “USPTO”) for composi |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| July 24, 2023 |
Exhibit 99.1 Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373 Absorption, distribution, metabolism, and excretion (ADME) and toxicology assays demonstrated rapid conversion of EB-373 to the active metabolite psilocin, consistent with previously reported animal pharmacokinetic (PK) studies CAMBRIDGE, Mass., July 24, 2023 – E |
|
| July 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 24, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| July 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 July 17, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction (Commission (I.R.S. Employer o |
|
| July 17, 2023 |
Exhibit 99.1 Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373 Orally administered EB-373 resulted in dose-dependent increase in psilocin blood concentration in pharmacokinetic (PK) animal studies, correlating to levels expected to be effective based on psilocybin data in humans Outcome of animal st |
|
| June 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENV |
|
| June 8, 2023 |
June 8, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 7, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| June 7, 2023 |
Exhibit 99.1 Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023) CAMBRIDGE, Mass., June 7, 2023 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today an |
|
| June 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 6, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| June 6, 2023 |
Corporate Presentation, dated 2023 (furnished pursuant to Item 7.01) Exhibit 99.1 |
|
| June 5, 2023 |
Exhibit 99.1 Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug Candidates New composition of matter claims establish intellectual property for Enveric’s EVM301 Series of novel small molecules designed to promote neuroplasticity without inducing hallucinations. CAMBRIDGE, Mass., June 5, 2023 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), |
|
| June 5, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 June 5, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 30, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 30, 2023 |
Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023 Exhibit 99.1 Enveric Biosciences Announces Poster Presentation at Canadian Neuroscience Meeting 2023 CAMBRIDGE, Mass., May 30, 2023 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced that research foundati |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 18, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 24, 2023 |
Exhibit 99.1 Enveric Biosciences Receives Notice of Allowance from USPTO for C4-Carboxylic Acid-substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug New composition of matter claims expand intellectual property for Enveric’s EVM201 Series CAMBRIDGE, Mass., May 24, 2023 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to t |
|
| May 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 24, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 22, 2023 |
Exhibit 99.1 Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders Research highlights the potential of Enveric’s EVM201 Series aimed at developing psilocin prodrugs with altered metabolic profiles that offer superior administration and treatment benefits, but reduce pharmacological exposure CAMB |
|
| May 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 22, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 19, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 19, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 19, 2023 |
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston Exhibit 99.1 Enveric Biosciences to Participate in 2023 BIO International Convention in Boston CAMBRIDGE, Mass., May 19, 2023 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today announced its participation in this ye |
|
| May 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 May 18, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission F |
|
| May 18, 2023 |
Exhibit 99.1 Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin Intellectual property describes composition of matter claims governing Enveric’s lead clinical candidate, EB-373, which is being developed for the treatment of anxiety disorder CAMBRIDGE, Mass., May 18, 2023 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: March 31, 2023 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| May 15, 2023 |
Press release dated May 15, 2023 Exhibit 99.1 Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights ● Announced cost reduction plan resulting in approximately 40% to 55% decrease in expenses and extension of financial runway into Q1 2024 ● Continued to advance pipeline of small molecule therapeutics for the treatment of mental health disorders, including EB-373 for the treatment of anxiety di |
|
| May 15, 2023 |
Exhibit 10.2 Execution Version CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. TERMINATION OF PRIOR AGREEMENTS AND MUTUAL RELEASE (THE “AGREEMENT”) This Agreement is made as of May , 2023 by and between Enveric Biosciences, Inc. (“Enveric”), Akos Biosci |
|
| April 13, 2023 |
Corporate Presentation, dated April 2023 (furnished pursuant to Item 7.01) Exhibit 99.1 |
|
| April 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 12, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| April 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 10, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| April 10, 2023 |
Exhibit 99.1 Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference CEO Joseph Tucker, Ph.D., to discuss Enveric’s pipeline and therapeutic opportunities in fireside chat and “NextGen Psychedelics” panel discussion CAMBRIDGE, Mass., April 10, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel |
|
| April 3, 2023 |
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results Exhibit 99.1 Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results Key Highlights ● Nominated EB-373 as lead development candidate for the treatment of anxiety disorders ● EB-373 is a next generation proprietary psilocin prodrug selected from Enveric’s EVM201 Series and developed leveraging the Company’s Psybrary™ drug discovery platform ● Established Austral |
|
| April 3, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 3, 2023 ENVERIC BIOSCIENCES, INC. (Exact name of Registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 31, 2023 |
Exhibit 21.1 SUBSIDIARIES OF ENVERIC BIOSCIENCES, INC. Subsidiary Jurisdiction of Organization Jay Pharma Inc. Ontario, Canada 1306432 B.C. Unlimited Liability Company British Columbia, Canada Enveric Biosciences Canada, Inc. British Columbia, Canada MagicMed USA, Inc. Massachusetts, USA Akos Biosciences, Inc. Enveric Therapeutics Pty. Ltd. Delaware, USA Adelaide, Australia |
|
| March 31, 2023 |
Exhibit 4.1 DESCRIPTION OF CAPITAL STOCK The following description sets forth certain material terms and provisions of our securities that are registered under Section 12 of the Securities Exchange Act of 1934, as amended. This description also summarizes relevant provisions of Delaware law. The following summary does not purport to be complete and is subject to, and is qualified in its entirety b |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the annual period ended: December 31, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, IN |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 23, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 23, 2023 |
Exhibit 99.1 Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373 EB-373, a proprietary psilocin prodrug, is on track to start its first-in-human clinical trial in the fourth quarter of 2023 CAMBRIDGE, Mass., March 23, 2023 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development |
|
| March 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 21, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 21, 2023 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications First-in-human clinical trial investigating Enveric’s lead product candidate, EB-373 targeting anxiety disorder expected to initiate in the fourth quarter of 2023 CAMBRIDGE, Mass., March 21, 2023 – Enveric Biosciences (NASD |
|
| March 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 March 14, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commission |
|
| March 14, 2023 |
Exhibit 99.1 Enveric Biosciences Announces Bioproduction Platform Using Novel Cane Toad Enzyme for Psychedelic-Inspired Drug Discovery Research details the bioproduction of novel indolethylamine-type drug candidates with potential use in psychiatric medicine CAMBRIDGE, Mass., March 14, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2023 ENVERIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commis |
|
| February 28, 2023 |
EX-10.1 2 ex10-1.htm Exhibit 10.1 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (this “Agreement”), dated as of February 22, 2023 to be effective as of March 13, 2023 (the “Effective Date”), entered into by and between Kevin Coveney (the “Executive”) and Enveric Biosciences, Inc. (the “Company”). The Company and the Executive shall be referred to herein as the “Parties.” RECITALS Whereas, the Com |
|
| February 28, 2023 |
Exhibit 99.1 Enveric Biosciences Appoints Kevin Coveney as Chief Financial Officer, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 30+ year pharmaceutical industry veteran joins Enveric’s executive team to lead company’s financial and capital markets activities. CAMBRIDGE, Mass., February 28, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology |
|
| February 23, 2023 |
Exhibit 99.1 Enveric Biosciences Names Lynn Gallant Vice President, Clinical Operations, and Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) Accomplished pharmaceutical industry leader brings to Enveric extensive experience in clinical operations, asset strategy and product development CAMBRIDGE, Mass., February 23, 2023 – Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 23, 2023 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| February 14, 2023 |
US29405E2081 / ENVERIC BIOSCIENCES INC / AdvisorShares Trust Passive Investment SC 13G 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 Enveric Biosciences, Inc. (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) 2940 |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enveric Biosciences, Inc. (Name of Issuer) Common Stock, $0.01 par value per share (Title of Class of Securities) 29405E208 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| February 7, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Enveric Biosciences, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29405E208 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 2) ENVERIC BIOSCIENCES, INC. f/k/a AMERI Holdings, Inc. (Name of Issuer) COMMON STOCK (Title of Class of Securities) 29405E109 (CUSIP Number) December 31, 2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) Check the appropriate box to designate t |
|
| January 20, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 Enveric Biosciences, Inc. Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee (2) Equity Common Stock, $0.01 par value per share Rule 457(c) and Rule 457(h) 128,401 (3) $ 2.79 (4) $ 358,238.79 $ 0.00011020 $ 39.4 |
|
| January 20, 2023 |
As filed with the Securities and Exchange Commission on January 20, 2023 As filed with the Securities and Exchange Commission on January 20, 2023 Registration No. |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: September 30, 2022 OR ? Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIEN |
|
| October 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2022 ENVERIC BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| October 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 October 23, 2022 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissi |
|
| October 24, 2022 |
Exhibit 99.2 Enveric Biosciences Advances Lead Candidate for the Treatment of Anxiety Disorders to IND-Enabling Studies — Next Generation Psilocin Prodrug, EB-373, Nominated to Advances to IND-Enabling Studies — —First Generation EVM101 Program for Cancer Related Distress has been discontinued — CAMBRIDGE, Mass. – October 24, 2022 - Enveric Biosciences Inc. (NASDAQ: ENVB) (“Enveric” or the “Compan |
|
| October 24, 2022 |
Investor Presentation, Q4 2022 (furnished herewith pursuant to Item 7.01) Exhibit 99.1 |
|
| October 6, 2022 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 20, 2022 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of in |
|
| October 6, 2022 |
Letter of Friedman LLP to the Securities and Exchange Commission, dated October 6, 2022. Exhibit 16.1 October 6, 2022 Securities and Exchange Commission 100 F Street, NE Washington, D.C. 20549 Re: Enveric Biosciences, Inc. Commission File Number 001-38286 Commissioners: We have read the statements made by Enveric Biosciences, Inc. under Item 4.01 of its Form 8-K dated September 23, 2022, as amended by the Current Report Form 8-K/A Amendment No.1 on October 6, 2022 and we agree with th |
|
| September 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| September 23, 2022 |
Changes in Registrant's Certifying Accountant UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 20, 2022 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commis |
|
| September 14, 2022 |
Investor Presentation, dated September 2022 (furnished herewith pursuant to Item 7.01) Exhibit 99.1 |
|
| September 14, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 14, 2022 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commis |
|
| September 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 September 9, 2022 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commiss |
|
| September 1, 2022 |
Shareholder Director Nominations UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 August 29, 2022 Date of Report (Date of earliest event reported) Enveric Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38286 95-4484725 (State or other jurisdiction of incorporation) (Commissio |
|
| August 12, 2022 |
Enveric Biosciences, Inc. 1,695,000 Shares of Common Stock Filed Pursuant to Rule 424(b)(3) Registration No. 333-266579 PROSPECTUS Enveric Biosciences, Inc. 1,695,000 Shares of Common Stock This prospectus relates to the resale by the selling stockholders named in this prospectus from time to time of up to 1,695,000 shares of our common stock, par value $0.01 per share. These 1,695,000 shares of common stock consist of: ? 116,000 shares of common stock (t |
|
| August 12, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the quarterly period ended: June 30, 2022 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number 001-38286 ENVERIC BIOSCIENCES, |
|
| August 9, 2022 |
Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, FL 34103 CORRESP 1 filename1.htm Enveric Biosciences, Inc. 4851 Tamiami Trail N, Suite 200 Naples, FL 34103 August 9, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Securities and Exchange Commission Washington, D.C. 20549 Attention: Jane Park Re: Enveric Biosciences, Inc. Registration Statement on Form S-3 Filed on August 5, 2022 File No. 333 |
